Paralel Advisors LLC Has $2.38 Million Stock Holdings in Amgen Inc. $AMGN

Paralel Advisors LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 23.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,565 shares of the medical research company’s stock after selling 2,020 shares during the quarter. Paralel Advisors LLC’s holdings in Amgen were worth $2,377,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the last quarter. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the period. Manning & Napier Advisors LLC boosted its holdings in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on AMGN shares. Truist Financial lifted their price objective on Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 target price on Amgen in a research note on Friday, June 5th. Sanford C. Bernstein raised their target price on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Cantor Fitzgerald lifted their price target on Amgen from $350.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, UBS Group lifted their price target on Amgen from $420.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $380.43.

Amgen Price Performance

Shares of Amgen stock opened at $433.73 on Friday. The firm has a market cap of $234.49 billion, a P/E ratio of 26.96, a price-to-earnings-growth ratio of 4.09 and a beta of 0.41. The firm’s 50-day simple moving average is $377.35 and its 200-day simple moving average is $361.40. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $443.20. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen Inc. will post 22.89 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s payout ratio is currently 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last quarter. Company insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Unusually heavy call-option activity points to increased bullish positioning. Investors purchased 79,035 call options, roughly 931% above typical volume, although options activity is speculative and does not guarantee future gains.
• Positive Sentiment: Argus raised its price target from $375 to $460 and upgraded Amgen to “Buy,” adding to the series of favorable analyst views. Argus price target report
• Positive Sentiment: Mizuho and Cantor Fitzgerald analysts also projected further appreciation for Amgen, reinforcing the bullish sentiment around the company’s earnings performance and pipeline. Mizuho Amgen forecast Cantor Fitzgerald Amgen outlook
• Positive Sentiment: Amgen has outperformed several major drugmakers in 2026, attracting investor interest as markets favor profitable pharmaceutical companies even without an obesity-drug franchise. Drugmaker stock performance comparison
• Neutral Sentiment: Biotech ETFs are benefiting from innovation, obesity-drug demand and merger activity, creating a favorable sector backdrop, though the article does not identify a specific new catalyst for Amgen. Biotech ETF growth article
• Negative Sentiment: Industry caution around obesity-drug development is a risk: investors are penalizing undifferentiated programs, and Amgen has reportedly trimmed some early-stage efforts. Obesity drug investment outlook

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.